Cargando…
The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia
Treatment intensification in people with type 2 diabetes following failure of basal insulin commonly involves the addition of a rapid-acting insulin analogue (basal plus one or more prandial doses; multiple daily injections) or by a switch to premixed insulin. Insulin degludec/insulin aspart (IDegAs...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230791/ https://www.ncbi.nlm.nih.gov/pubmed/32290465 http://dx.doi.org/10.3390/jcm9041091 |
_version_ | 1783535038485233664 |
---|---|
author | Glastras, Sarah J. Cohen, Neale Dover, Thomas Kilov, Gary MacIsaac, Richard J. McGill, Margaret Fulcher, Greg R. |
author_facet | Glastras, Sarah J. Cohen, Neale Dover, Thomas Kilov, Gary MacIsaac, Richard J. McGill, Margaret Fulcher, Greg R. |
author_sort | Glastras, Sarah J. |
collection | PubMed |
description | Treatment intensification in people with type 2 diabetes following failure of basal insulin commonly involves the addition of a rapid-acting insulin analogue (basal plus one or more prandial doses; multiple daily injections) or by a switch to premixed insulin. Insulin degludec/insulin aspart (IDegAsp), comprising rapid-acting insulin aspart and ultra-long-acting insulin degludec in solution, enables both fasting and post-prandial glucose control, with some advantages over other treatment intensification options. These include straightforward dose titration, flexibility in dose timing, low injection burden, simplicity of switching and a lower risk of hypoglycaemia. In Australia, where insulin degludec on its own is not available, IDegAsp enables patients to still benefit from its ultra-long-acting properties. This review aims to provide guidance on where and how to use IDegAsp. Specifically, guidance is included on the initiation of IDegAsp in insulin-naïve patients, treatment intensification from basal insulin, switching from premixed or basal-bolus insulin to IDegAsp, up-titration from once- to twice-daily IDegAsp and the use of IDegAsp in special populations or situations. |
format | Online Article Text |
id | pubmed-7230791 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72307912020-05-22 The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia Glastras, Sarah J. Cohen, Neale Dover, Thomas Kilov, Gary MacIsaac, Richard J. McGill, Margaret Fulcher, Greg R. J Clin Med Review Treatment intensification in people with type 2 diabetes following failure of basal insulin commonly involves the addition of a rapid-acting insulin analogue (basal plus one or more prandial doses; multiple daily injections) or by a switch to premixed insulin. Insulin degludec/insulin aspart (IDegAsp), comprising rapid-acting insulin aspart and ultra-long-acting insulin degludec in solution, enables both fasting and post-prandial glucose control, with some advantages over other treatment intensification options. These include straightforward dose titration, flexibility in dose timing, low injection burden, simplicity of switching and a lower risk of hypoglycaemia. In Australia, where insulin degludec on its own is not available, IDegAsp enables patients to still benefit from its ultra-long-acting properties. This review aims to provide guidance on where and how to use IDegAsp. Specifically, guidance is included on the initiation of IDegAsp in insulin-naïve patients, treatment intensification from basal insulin, switching from premixed or basal-bolus insulin to IDegAsp, up-titration from once- to twice-daily IDegAsp and the use of IDegAsp in special populations or situations. MDPI 2020-04-11 /pmc/articles/PMC7230791/ /pubmed/32290465 http://dx.doi.org/10.3390/jcm9041091 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Glastras, Sarah J. Cohen, Neale Dover, Thomas Kilov, Gary MacIsaac, Richard J. McGill, Margaret Fulcher, Greg R. The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia |
title | The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia |
title_full | The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia |
title_fullStr | The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia |
title_full_unstemmed | The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia |
title_short | The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia |
title_sort | clinical role of insulin degludec/insulin aspart in type 2 diabetes: an empirical perspective from experience in australia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230791/ https://www.ncbi.nlm.nih.gov/pubmed/32290465 http://dx.doi.org/10.3390/jcm9041091 |
work_keys_str_mv | AT glastrassarahj theclinicalroleofinsulindegludecinsulinaspartintype2diabetesanempiricalperspectivefromexperienceinaustralia AT cohenneale theclinicalroleofinsulindegludecinsulinaspartintype2diabetesanempiricalperspectivefromexperienceinaustralia AT doverthomas theclinicalroleofinsulindegludecinsulinaspartintype2diabetesanempiricalperspectivefromexperienceinaustralia AT kilovgary theclinicalroleofinsulindegludecinsulinaspartintype2diabetesanempiricalperspectivefromexperienceinaustralia AT macisaacrichardj theclinicalroleofinsulindegludecinsulinaspartintype2diabetesanempiricalperspectivefromexperienceinaustralia AT mcgillmargaret theclinicalroleofinsulindegludecinsulinaspartintype2diabetesanempiricalperspectivefromexperienceinaustralia AT fulchergregr theclinicalroleofinsulindegludecinsulinaspartintype2diabetesanempiricalperspectivefromexperienceinaustralia AT glastrassarahj clinicalroleofinsulindegludecinsulinaspartintype2diabetesanempiricalperspectivefromexperienceinaustralia AT cohenneale clinicalroleofinsulindegludecinsulinaspartintype2diabetesanempiricalperspectivefromexperienceinaustralia AT doverthomas clinicalroleofinsulindegludecinsulinaspartintype2diabetesanempiricalperspectivefromexperienceinaustralia AT kilovgary clinicalroleofinsulindegludecinsulinaspartintype2diabetesanempiricalperspectivefromexperienceinaustralia AT macisaacrichardj clinicalroleofinsulindegludecinsulinaspartintype2diabetesanempiricalperspectivefromexperienceinaustralia AT mcgillmargaret clinicalroleofinsulindegludecinsulinaspartintype2diabetesanempiricalperspectivefromexperienceinaustralia AT fulchergregr clinicalroleofinsulindegludecinsulinaspartintype2diabetesanempiricalperspectivefromexperienceinaustralia |